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ABSTRACT 
Aim: The aim of the present study was to explore prognostic factors for survival in a 
large series of surgically treated meningiomas. 
 
Material & methods: Retrospective study of 1469 consecutive craniotomies for 
histological verified intracranial meningiomas at the Oslo University Hospital in the 
time period 1990-2010. 
 
Results: The median age at surgery was 58 years (range 10-92 years), with a male-
to-female ratio of 1:2.36. Follow-up was 100%. Median observation time was 6.9 
years (range 0.0-20.9). The surgical mortality was 1.9%, 2.7% were reoperated for 
hematoma and 2.6% reoperated for deep infection. The 1-, 5- and 10-years OS after 
surgery was 96%, 87% and 76%, respectively. Increasing age, male sex, WHO grade 
II/III and residual tumor after surgery were identified as significant negative 
prognostic factors. In this series, tumor location was not associated with OS. 
 
Conclusions: The 1-, 5- and 10-years OS after surgery was 96%, 87% and 76%, 
respectively. Increasing age, male sex, WHO grade II/III and residual tumor after 
surgery were identified as negative prognostic factors. In this series, tumor location 
was not associated with OS. In our opinion the goal of meningioma surgery should 
always be complete resection. 
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INTRODUCTION 
 
The incidence of primary intracranial tumors in Norway is 24.2 per 100,000 person-
years and meningiomas account for 31% of these tumors, with an incidence of 7.5 
per 100,000 person-years.
1
 There has been an increase in new cases of 
meningiomas during the last decades.
2
 Females have a well-known increased risk of 
developing meningiomas, and meningiomas show a marked and quite linear increase 
in incidence with advancing age.
3, 4
 
 
According to WHO meningiomas are classified into three histological grades with 
increasing malignancy. Meningiomas are further subdivided according to dural 
attachment/origin; e.g. convexity-, parasagittal-, falx-, lateral sphenoid wing, 
supratentorial skull base, posterior fossa- and intraventricular meningiomas.
5
  
 
The main treatment strategy for meningiomas is surgical resection of symptomatic 
meningiomas. The aim is complete resection including resection of dural attachment 
in order to achieve Simpson resection grade I.6 Subtotally resected tumors are either 
observed or the residual tumor is subjected to stereotactic radiosurgery (SRS). 
Fractionated radiotherapy of the tumor region after surgical resection is considered in 
cases of WHO grade II and III tumors. The following variables have in previous 
studies been identified as prognostic factors for survival of meningioma patients after 
surgical resection: age, gender, preoperative Karnofsky performance status, tumor 
location (dural attachment), WHO grade, Simpson resection grade, high MIB-1 index, 
loss of chromosome 1-p and expression of vascular endothelial growth factor 
(VEGF). 6-8, 10-21, 23-25, 28-35, 40, 44-57 
 
The aim of the present study was to explore the validity of some of the above-
mentioned prognostic factors for survival in our large consecutive series of surgically 
treated meningiomas (n = 1469). 
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MATERIALS AND METHODS 
PATIENTS 
A total of 1469 consecutive craniotomies for histological verified intracranial 
meningiomas at the Oslo University Hospital in the time period 1990-2010 were 
included in this study (Table 1). Reviewing operative protocols identified patients 
treated in 1990 – 2002, while patients operated after 2002 were identified from our 
prospectively collected tumor database. 
 
Data was obtained from patients’ medical records from Oslo University Hospital, 
including clinic records of pre- and postoperative visits, operative notes, discharge 
summaries, pathology reports, and radiological data. The preoperative, post-contrast 
imaging studies were reviewed to confirm tumor location/dural attachment. In each 
case, the extent of resection was graded using the Simpson grading scale (Grade 1. 
Macroscopically complete removal with excision of dural attachment and abnormal 
bone, Grade 2. Macroscopically complete with endothermic coagulation of dural 
attachment, Grade 3. Macroscopically complete without resection or coagulation of 
dural attachment or of its extradural extensions, Grade 4. Subtotal resection, and 
Grade 5. Simple decompression/biopsy).
6
 This information was obtained from the 
operative notes and postoperative CT/MR. 
 
The following variables were registered: gender, age, presenting symptoms 
(seizures, increased intracranial pressure, neurological deficits), tumor location 
(convexity, parasagittal, falx, lateral sphenoid wing, supratentorial skull base, 
posterior fossa and intraventricular), Simpson resection grade
6
, re-operation for 
postoperative hematoma (extradural, subdural, intracerebral), reoperation for 
postoperative infection (extradural, subdural, intracerebral or infected bone flap), 
WHO histological grade. The criteria for meningioma grading have changed over the 
last 20 years. From 1990 to 2001, the tumors were classified as benign, atypical or 
anaplastic. The present WHO-grading system for meningioma was implemented in 
2001, which divides the tumors into grade I, II and III. For this study, we reclassified 
the tumors operated before 2001 to the present WHO classification; benign = WHO 
grade I, atypical = WHO grade II and anaplastic = WHO grade III. 
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The endpoint of the study was overall survival, defined as time from resection to 
death. Vital status (dead or alive) and time of death was obtained from the 
Norwegian Population Registry (Folkeregisteret) January 27th, 2011. The surgical 
mortality was defined as death of any cause within 30 days of surgery. 
 
ETHICS 
The Data Protection Official at Oslo University Hospital approved the study.  
 
STATISTICS 
SPSS/PASWStatistics 18.0.3 for Windows (SPSS Inc.) and R v 2.15 were used for 
statistical analyses. Summaries of the data are shown using counts and percentages. 
For the survival analysis, we first generated a plot using the Kaplan-Meier estimator.  
The general population curve was obtained by matching each meningioma patient on 
sex, age within 10 years and cohort on lifetables from Statistics Norway 
(http://www.ssb.no/). Uni- and multivariate Cox regression modeling was used for 
further survival analysis after ascertaining that the assumptions of proportional 
hazard were fulfilled. Significance was defined as p < 0.05. 
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RESULTS  
 
Patient characteristics 
The median age at surgery was 58 years (range 10-92 years), with a male-to-female 
ratio of 1:2.36. Follow-up was 100%. Median observation time was 6.9 years (range 
0.0-20.9). Patient characteristics are given in Table 1. 
 
Quality parameters for surgery 
28 patients died within 30 days of surgery, yielding a surgical mortality rate of 1.9%. 
The surgical mortality decreased from 3.5% in 1990-1994 to 1.1% in 2005-2010 
(Table 2). The rate of postoperative hematomas requiring surgical evacuation was 
2.7% (n=40). The median time to reoperation was 2 days (range 0-232). 38 patients 
(2.6%) were reoperated due to deep infection after a median of 42 days (range 2-
2324). The rates of reoperation for postoperative hematoma or local infection showed 
no significant change over time (Table 2).   
 
Overall survival (OS) 
1-, 5- and 10-year overall survival (OS) after surgery was 95.5%, 86.5% and 75.9%, 
respectively. Figure 1 displays the Kaplan-Meier curves stratified by WHO-grade. A 
Kaplan-Meier curve matched by age, sex and cohort to the meningioma patients is 
also shown for reference. There is a significantly worse survival for patients harboring 
a meningioma, irrespective of WHO-grade, compared to the general population 
(p<0.05). Furthermore, WHO II and III grade portends a worse prognosis than WHO 
grade I. 
 
A univariate- and multivariate regression analysis of variables with possible 
association to OS of meningioma patients after tumor resection is presented in Table 
3. The following parameters were identified as negative prognostic factors with 
respect to OS: Increasing age, male sex, WHO grade II/III tumors and residual tumor 
after surgery. Tumor location was in this material not associated with survival. 
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WHO grade II/III tumors were significantly more frequent in males than females 
(Table 4). 
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DISCUSSION 
In this series of 1469 consecutive patients treated with craniotomy and surgical 
resection of meningioma the surgical mortality was 1.9%, 2.7% were reoperated for 
hematoma and 2.6% reoperated for deep infection. The 1-, 5- and 10-years OS after 
surgery was 96%, 87% and 76%, respectively. Increasing age, male sex, WHO grade 
II/III and residual tumor after surgery were identified as negative prognostic factors. In 
this series, tumor location was not associated with OS. To the best of our knowledge, 
this is one of the largest single-institution, clinically based surgical series of 
intracranial meningioma published. 
 
Quality of surgery 
Quality of surgery is one of many factors that have an impact on OS. Thus, when 
addressing risk factors for OS the quality of surgery should also be discussed. 
Surgical mortality, the rate of postoperative hematoma, the rate of deep 
postoperative infection and neurological deterioration after surgery are all well 
accepted indicators for quality of surgery. Three of the four mentioned quality 
indicators were included in this study. Unfortunately, the retrospective chart review 
gave no reliable information regarding neurological deterioration. 
 
Surgical mortality 
The surgical mortality after craniotomy for tumors is reported to be between 0 – 
10.8%.
9-16 
Our surgical mortality of 1.9% is in the lower part of this specter. The 
decrease in surgical mortality over time is most likely multifactorial; e.g. better 
preoperative imaging, improvements in neuro-anesthesiology and improvements in 
surgical technique. This positive time trend with respect to surgical mortality has also 
been reported by others.
14, 15
 
 
Reoperation for postoperative hematoma 
The rate for postoperative hematoma after craniotomy for tumor has been reported to 
be between 0.6% and 4%.
9, 10, 17-25
 Palmer et al identified meningioma as a risk factor 
for postoperative hematoma compared to intrinsic tumors.
17
 However, in a large 
series from our hospital studying complications after craniotomy there was no 
difference in hematoma rates after surgery for intrinsic or extrinsic intracranial 
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tumors.
9
 Our hematoma rate of 2.7% is in the middle of the range reported for 
meningiomas. Postoperative hematoma is a contributor to surgical mortality and 
morbidity.
9
 
 
Reoperation for deep infection 
2.6% of the patients in our series were complicated with a surgical site infection 
(extradural, subdural, intracerebral or infected bone flap) that required reoperation. 
The rate of reoperation for deep infection after craniotomy for tumor is reported to be 
between 0.6% and 6.6% (reviewed in Lassen et al).
9
 Reviewing only meningiomas, 
the rate ranges from 0.5% to 6.2%.
10, 19, 20, 22, 24, 26, 27
 Postoperative infection causes 
prolonged hospitalization and increased costs. However, the long-term result with 
regard to survival and neurological outcome is less affected than after postoperative 
hematoma.
10
 
 
Overall survival  and factors associated with overall survival 
The overall survival rates following craniotomy for meningioma has been reported to 
be 82 – 91% at 1-year, 55 – 83% at 5-years and 33 – 77% at 10-years.
6, 14, 28-30
 In our 
series the 1-, 5- and 10-year survival rates were 96%, 87% and 76%, respectively. 
 
Age 
We found age to be a negative prognostic factor for OS. This has been widely 
reported in previous studies.
14, 15, 21, 23, 28, 31-33
 Mortality not related to the meningioma 
itself is considerable in the elderly patients. Thus, the OS of meningioma patients 
should be compared with the expected OS of a general population comparable to the 
patients. Doing this, we found the OS following craniotomy for any meningioma to be 
significantly worse than for the matched general Norwegian population, both for WHO 
grade I and WHO grade II/III patients. Others have reported insignificant differences 
in survival between patients with WHO grade I meningioma and the matched general 
population.
34
 Although higher age is associated with reduced OS, it should not alone 
be used as a selection criterion, as quality of life following meningioma surgery is 
improved in the majority of elderly patients.
24, 25, 35
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Sex 
It is well known that women develop meningiomas to a greater extent than men. The 
mechanisms for this are not entirely understood, but endocrinological influence is 
believed to play an important role.
36-38
 Nonetheless, overall survival was in this series 
found to be worse for men. This is in accordance with previous studies.
15, 28, 39
  
Contrary to these findings, Duntze et al reported female sex as a negative prognostic 
factor.
33
 The fact that their study included only 36 patients and excluded WHO grade 
I is of relevance. A possible explanation for the poorer OS in men is the greater 
frequency of WHO grade II/III tumors in men compared to women. This has also 
been commented in previous series.
14, 40-44
 Interestingly, Whittle et al showed that 
progesterone activity correlates inversely with malignancy in meningiomas
45
, the 
opposite of what is believed for benign meningiomas. 
 
Simpson resection grade 
Many previous publications have addressed the relevance of radical tumor resection 
and its association to tumor recurrence.
6, 18, 46-48 
The relation to OS has not been 
discussed to the same extent. Chan and Thompson found a difference in 3.3 years in 
average survival time between total excision and partial removal of tumor.
10
 A study 
published by Sughrue et al in 2010 indicated that differences in outcome between 
Simpson grade 1 and 2 were negligible, although only reviewing WHO grade I 
meningiomas.
49
 In our series, subtotal resection (Simpson grade 4/5) was associated 
with reduced OS. In our opinion the goal of meningioma surgery is Simpson resection 
grade 1-3, depending on tumor location. 
 
WHO grade 
WHO grade was as a significant prognostic factor with respect to OS in our material, 
as in previous series, with poorer survival for WHO grade II and III.
10, 14, 15, 23, 29, 32, 50, 
51
 In our series, the 5-year survival rate for WHO grade I, II and III were 88%, 75% 
and 66%, respectively. The range of reported survival rates for the different WHO 
grades are wide, especially for grade III. The 5-year survival rate for WHO grade I 
tumors is reported to be 75-93%, for WHO grade II 50-80% and for WHO grade III 8 
– 62%.
29, 31-34, 40, 44, 52
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Tumor location 
No statistical difference in survival for the various tumor locations was found in our 
study. Published series has so far given no general consensus regarding the impact 
of tumor location with respect to survival.
13, 15, 16, 19, 51, 53
 
 
Other prognostic factors 
There are other well-known prognostic factors that where not studied in our series. 
The following factors have in previous studies been associated with reduced OS: 
impaired preoperative neurological function, lack of calcification in the tumor, a high 
MIB-1 index, loss of chromosome 1-p and expression of vascular endothelial growth 
factor (VEGF).
10, 51, 54-57
 
 
Strengths of the study 
The strengths of this study lie in the setting, design and follow-up. The data were 
restricted to one health centre only (Oslo University Hospital), thereby reducing the 
possible confounding effect of differences in the access to health care services 
between health centers. Thus, we have avoided the selection bias inherently present 
in large multi-center studies. The two-neurosurgical units performing these surgeries 
are within a geographically well-defined area. As the study includes all craniotomies 
performed for histologically verifiable meningiomas, there is no selection bias. With 
respect to data quality, we only used end points that are easily verifiable (i.e. 
mortality, reoperation for hematomas and reoperations for infections).  
 
Limitation of the study 
The main limitation of the study is the retrospective design. 
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CONCLUSIONS 
The 1-, 5- and 10-years OS after surgery was 96%, 87% and 76%, respectively. 
Increasing age, male sex, WHO grade II/III and residual tumor after surgery were 
identified as negative prognostic factors. In this series, tumor location was not 
associated with OS. In our opinion the goal of meningioma surgery should always be 
complete resection. 
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Figure 1. Kaplan-Meier curves for OS stratified by WHO-grade. A Kaplan-Meier curve 
matched by age, sex and cohort to the meningioma patients is also shown for 
reference (= general population). 
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Table 1. Patient characteristics 
  N (%) 
All  1469 (100) 
Gender Females 1033 (70.3) 
 Males 436 (29.7) 
Age 15 – 29 17 (1.2) 
 30 – 39 126 (8.6) 
 40 – 49 256 (17.4) 
 50 –59 396 (27.0) 
 60 – 69 352 (24.0) 
 70 –79 273 (18.6) 
 80+ 49 (3.3) 
Signs/symptoms at presentation  1389 (94.6) 
Tumor location Convexity 391 (26.6) 
 Parasagittal 201 (13.7) 
 Falx 164 (11.1) 
 Lat sphenoid wing 94 (6.4) 
 Skullbase ST1 398 (27.1) 
 Posterior fossa 198 (13.5) 
 Intraventricular 23 (1.6) 
Surgical approach Supratentorial 1271 (86.5) 
 Infratentorial 198 (13.5) 
Simpson resection grade2 1 575 (39.1) 
 2 504 (34.2) 
 3 79 (5.4) 
 4 302 (20.6) 
 5 8 (0.5) 
WHO grade I 1359 (92.5) 
 II 78 (5.3) 
 III 32 (2.2) 
 
                                            
1 Supratentorial 
2 Information of radicality missing for two patients. 
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Table 2. Time trend of surgical mortality,  
Time 
period 
Total number of 
patients 
Surgical mortality 
(%) 
Reop for Hematoma 
(%) 
Reop for deep 
infection (%) 
1990-1994 260 3.5 1.5 1.2 
1995-1999 280 2.5 3.9 2.1 
2000-2004 381 1.6 2.6 3.1 
2005-2010 548 1.1 2.7 3.1 
TOTAL 1469 1.9 2.7 2.6 
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Table 3. Univariate and multivariate Cox regression analyses of factors associated 
with overall survival 
Variable Univariate analysis Multivariate analysis 
 1HR 95% conf.int HR 95% conf.int 
Age 1.093 (1.081, 1.105)***  1.095 (1.083, 1.107)***  
Sex     
 Male Ref 
 Female 0.537 (0.432, 0.669)***  0.659 (0.526, 0.827)***  
Dural attachment     
 Convexity Ref 
 Posterior Fossa 0.965 (0.673, 1.386)  0.976 (0.626, 1.524)  
 Falx 0.909 (0.607, 1.362)  0.994 (0.639, 1.545)  
 Lateral sphenoid wing 0.924 (0.556, 1.534)  1.161 (0.672, 2.007)  
 Skullbase supratentorial 1.038 (0.776, 1.389)  1.157 (0.794, 1.685)  
 Parasagittal 1.198 (0.849, 1.691)  0.994 (0.674, 1.466)  
 Intraventricular 0.748 (0.237, 2.366)  1.512 (0.474, 4.828)  
Histological grade     
 WHO I Ref 
 WHO II (atypic) 2.313 (1.610,3.322)***  2.200 (1.507,3.212)***  
 WHO III (anaplastic) 3.412 (2.207, 5.275)***  3.074 (1.956, 4.832)***  
Simpson resection grade     
 1 Ref 
 2 0.940 (0.714, 1.236)  0.982 (0.701, 1.376)  
 3 1.062 (0.636, 1.775)  0.928 (0.542, 1.590)  
 4 2.062 (1.571, 2.707)***  2.358 (1.660, 3.348)***  
 5 2.189 (0.694, 6.900)  1.700 (0.416, 6.943)  
 
1HR = Hazard Ratio 
    
* p<0.05, ** p<0.01, *** p<0.001  
 
Table 4. Gender and WHO grade. 
 Male % Female % 
WHO I 89 94 
WHO II 7.3 4.5 
WHO III 3.7 1.5 
TOTAL 100  100 
 
